Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Generation Bio (GBIO) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Generation Bio (GBIO) over the last 5 years, with Q3 2025 value amounting to -$2000.0.

  • Generation Bio's Cash from Financing Activities rose 3333.33% to -$2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $215000.0, marking a year-over-year increase of 1748.63%. This contributed to the annual value of $250000.0 for FY2024, which is 9930.2% down from last year.
  • Generation Bio's Cash from Financing Activities amounted to -$2000.0 in Q3 2025, which was up 3333.33% from $80000.0 recorded in Q2 2025.
  • Over the past 5 years, Generation Bio's Cash from Financing Activities peaked at $213.0 million during Q1 2021, and registered a low of -$131000.0 during Q3 2023.
  • Over the past 5 years, Generation Bio's median Cash from Financing Activities value was $99000.0 (recorded in 2023), while the average stood at $13.9 million.
  • Over the last 5 years, Generation Bio's Cash from Financing Activities had its largest YoY gain of 6869230.77% in 2023, and its largest YoY loss of 10140.66% in 2023.
  • Quarter analysis of 5 years shows Generation Bio's Cash from Financing Activities stood at $435000.0 in 2021, then crashed by 80.92% to $83000.0 in 2022, then fell by 7.23% to $77000.0 in 2023, then surged by 87.01% to $144000.0 in 2024, then tumbled by 101.39% to -$2000.0 in 2025.
  • Its Cash from Financing Activities stands at -$2000.0 for Q3 2025, versus $80000.0 for Q2 2025 and -$7000.0 for Q1 2025.